Under the exclusive distribution agreement, Ferrer has gained rights to sell the tests in Germany, France, Italy, and Portugal, in addition to a current agreement signed in 2007 covering Spain. The companies are also discussing the possibility of future cooperation and expansion into other parts of the world.
MammaPrint is a prognostic test that uses a 70-gene signature to indicate risk of breast cancer tumor recurrence, and CupPrint is a gene expression profiling service which offers a fast and reliable method of identifying the primary tumor site in cancer of unknown primary (CUP).
Carlos de Lecea, vice president, international and business development at Ferrer, said: “Both tests provide valuable information that can be used to guide the therapeutic decision making process of oncologists, opening the door to a more personalized treatment for cancer patients.”